Enterprise Value

1.991B

Cash

598M

Avg Qtr Burn

-75.19M

Short % of Float

8.92%

Insider Ownership

1.48%

Institutional Own.

-

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Approved

Quarterly sales

Vorasidenib (Pan-IDHm inhibitor) Details
Glioma, Brain tumor

Big Mover™

Susp. Mover™

PDUFA

Approval decision

Phase 3

Data readout

PYRUKYND (Mitapivat) (pyruvate kinase R (PKR) activator) Details
Pyruvate Kinase Deficiency

Big Mover™

Susp. Mover™

Phase 3

Data readout

Phase 3

Update

AG-946 Details
Myelodysplastic syndrome

Phase 2b

Initiation

AG-181 Details
Phenylketonuria

Phase 1

Data readout